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Abstract: Anderson-Fabry disease (FD) is a rare, progressive, multisystem storage disorder caused
by the partial or total deficit of the lysosomal enzyme ↵-galactosidase A (↵-Gal A). It is an X-linked,
lysosomal enzymopathy due to mutations in the galactosidase alpha gene (GLA), encoding the ↵-Gal
A. To date, more than 900 mutations in this gene have been described. In our laboratories, the study
of genetic and enzymatic alterations related to FD was performed in about 17,000 subjects with a
symptomatology referable to this disorder. The accumulation of globotriaosylsphingosine (LysoGb3)
was determined in blood of positives. Exonic mutations in the GLA gene were detected in 471 patients
(207 Probands and 264 relatives): 71.6% of mutations were associated with the classic phenotype,
19.8% were associated with the late-onset phenotype, and 8.6% of genetic variants were of unknown
significance (GVUS). The accumulation of LysoGb3 was found in all male patients with a mutation
responsible for classic or late-onset FD. LysoGb3 levels were consistent with the type of mutations
and the symptomatology of patients. ↵-Gal A activity in these patients is absent or dramatically
reduced. In recent years, confusion about the pathogenicity of some mutations led to an association
between non-causative mutations and FD. Our study shows that the identification of FD patients is
possible by associating clinical history, GLA gene analysis, ↵-Gal A assay, and blood accumulation of
LysoGB3. In our experience, LysoGB3 can be considered a reliable marker, which is very useful to
confirm the diagnosis of Fabry disease.
Keywords: Fabry disease; GLA gene; LysoGb3
1. Introduction
Anderson-Fabry (or Fabry) disease (FD) (OMIM #301500) takes the name from the two
dermatologists that independently described for the first time the pathology at the end of 1800 [1].
It is an X-linked, lysosomal enzymopathy caused by mutations in the GLA gene, encoding the
↵-galactosidase A (↵-Gal A) [2]. FD is a sphingolipidosis that is considered rare, with a prevalence of
1:40,000. However, recent studies have showed that this disorder is much more widespread than is
commonly believed [3,4].
Fabry disease is a lysosomal storage disorder due to a functional defect of the enzyme ↵-Gal A.
This deficit is responsible for the alteration of the metabolism of some glycosphingolipids, mainly
globotriaosylceramide (Gb3), which consequently build up in the lysosomes of different cellular types,
mostly in vascular endothelium cells [5]. This results in systemic symptomatology with renal, cardiac,
and cerebrovascular involvement, which may lead, at the fourth or fifth decade of life, to premature
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death [6]. First symptoms can occur at different ages, usually during childhood, and show different
severity and clinical courses. The classic clinical manifestations of FD occur during pediatric age
with lancinating acroparesthesias in the extremities. The autonomic nervous system impairment is
responsible for alteration of sweating and thermoregulation disorder: during fever or physical exertion,
FD patients can manifest typical crises of pain. Gastrointestinal pain, associated with diarrhea and
sensation of abdominal fullness, is caused by the involvement of the vegetative local system. The skin
in FD can manifest the typical angiokeratomas localized mainly in the swimsuit area or throughout
the body (angiokeratomas corporis diffusum). Moreover, patients can have lymphedemas mostly in
the lower limbs. The eye, like in many neuro-metabolic diseases, can show different signs such as
the typical cornea verticillata, cataract, and telangiectasia of the conjunctiva. The function of renal
cells is compromised by the storage of glycosphingolipids, leading to a progressive nephropathy
that is one of the most critical manifestations of the disease. The hearth of FD patients frequently
shows a left ventricular hypertrophy, seemingly idiopathic, and an impairment of valvular apparatus
and intracardiac conduction. This involvement can cause various complications, such as cardiac
failure or arrhythmic pathology, which can lead to death caused by myocardial infarction. Besides the
impairment of the peripheral nervous system, FD patients can present an involvement of the brain
with juvenile ischemic strokes and possible hemorrhagic episodes. In addition to the classic phenotype,
atypical variants were described in patients with a milder symptomatology, an involvement of a
single organ, and late-onset [7–9]. Due to the X-linked transmission of FD, female patients have long
been considered only carriers. Conversely, they can develop significant signs and symptoms of the
disease, even if the phenotype is generally less severe [10]. Furthermore, female patients usually show
a variable symptomatology, because of the lyonization of the X-chromosome [11].
Nowadays the diagnosis of FD is still difficult, especially because its clinical manifestations
overlap with the ones of other pathologies, and, for this reason, there is a wide possibility of differential
diagnoses made by different medical specialists [12]. The diagnostic error is a concrete risk, and it
determines an underestimation of the real number of affected subjects [13]. To date, more than
900 mutations in the GLA gene were described (Human Gene Mutation Database, www.hgmd.org),
however not all these mutations are responsible for FD. A genetic variant can be unambiguously
related to a disease and explain the phenotype of a patient, but not all genetic variants are involved in
the patient’s symptomatology. Some variations may be only polymorphisms, individual variability,
and these alterations could be interpreted, in certain cases, as a risk factor for the development of
a disease. Fabry disease is suspected on the basis of clinical and anamnestic-familial data, and it is
confirmed by genetic and enzymatic assays, such as the detection of the specific genetic alteration and
the evaluation of ↵-Gal A activity, which could be null or deficient. Also, the determination of the
enzyme substrates, Gb3 and its derivative globotriaosylsphingosine (LysoGb3), provides an important
diagnostic support [14].
2. Results
Since 2005, our research group, operating at the Center for Research and Diagnosis on lysosomal
storage diseases of the Institute of Biomedicine and Molecular Immunology of the National Research
Council of Italy (IBIM-CNR) located in Palermo, has been devoted to the study of Fabry disease.
In these years, in a case-finding project, we studied about 17,000 subjects (average age 47 years old,
55.9% males and 44.1% females, with average ages, respectively, of 47.9 and 45.2 years old) with clinical
manifestations attributable to Fabry disease. In this population, we identified 207 Probands with a
genetic alteration in coding regions or in regulatory portions (splicing sites) of the GLA gene (Table 1).
In particular, in these subjects we detected 81 different mutations, 25 of which were described by us
for the first time in the world (Table 2). Figure 1 shows the mutations, divided into classes according
to the phenotype of patients in whom these mutations were identified. The study was extended to
the relatives of these patients and identified another 264 subjects with mutation in the exons of GLA,
thus reaching 471 individuals positive in the genetic test for FD (Table 3).
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Table 1. Characteristics of the 207 Probands identified and the clinical unit from which they came.
GVUS: genetic variants of unknown significance. Enzyme activity is measured in nmol/mL/h; normal
values > 3 nmol/mL/h. LysoGb3 is measured in nmol/L; normal values 0.08–1.13 nmol/L.
Overall Probands Male Probands Female Probands
Patients (%) 207 96 (46.4%) 111 (53.6%)
Average age [min-max] 44.9 [0–85] 42.3 [0–69] 47.0 [4–85]
Average ↵-Gal A activity 4.7 1.8 7.2
Average LysoGb3 11.9 24.4 2.0
Nephrology % 37.2 38.6 36.1
Neurology % 23.7 13.5 32.4
Cardiology % 18.4 22.9 14.4
Pediatrics % 13.0 17.7 9.0
Metabolic diseases % 2.4 2.1 2.7
Internal medicine % 1.9   3.6
Other % 3.4 5.2 1.8
Classic phenotype (%) 72 (34.8%) 45 (46.9%) 27 (24.3%)
Late-onset (%) 37 (17.9%) 24 (25.0%) 13 (11.7%)
GVUS (%) 98 (47.3%) 27 (28.1%) 71 (64.0%)
Classic Phenotype Probands Male Probands Female Probands
Patients (%) 72 45 (62.5%) 27 (37.5%)
Average age [min-max] 45.8 [0–73] 45.4 [0–57] 46.5 [18–73]
Average ↵-Gal A activity 1.8 0.1 4.7
Average LysoGb3 27.9 43.3 4.8
Nephrology % 47.2 48.9 44.5
Neurology % 13.9 11.1 18.5
Cardiology % 19.4 20.0 18.5
Pediatrics % 11.1 13.4 7.4
Metabolic diseases % 5.6 2.2 11.1
Internal medicine %      
Other % 2.8 4.4  
Late-Onset Probands Male Probands Female Probands
Patients (%) 37 24 (64.9%) 13 (35.1%)
Average age [min-max] 45.0 [0–78] 44.7 [0–69] 45.5 [14–78]
Average ↵-Gal A activity 2.1 0.6 4.5
Average LysoGb3 4.7 5.5 3.1
Nephrology % 13.5 20.8  
Neurology % 18.9 4.2 46.1
Cardiology % 37.9 41.6 30.8
Pediatrics % 27.0 29.2 23.1
Metabolic diseases %      
Internal medicine %      
Other % 2.7 4.2  
GVUS Probands Male Probands Female Probands
Patients (%) 98 27 (27.6%) 71 (72.4%)
Average age [min-max] 44.2 [1–85] 34.0 [1–58] 47.3 [4–85]
Average ↵-Gal A activity 8.2 6.2 9.0
Average LysoGb3 0.9 0.8 0.9
Nephrology % 38.8 37.1 39.4
Neurology % 32.6 25.9 35.2
Cardiology % 10.2 11.1 9.9
Pediatrics % 9.2 14.8 7.1
Metabolic diseases % 1.0 3.7  
Internal medicine % 4.1   5.6
Other % 4.1 7.4 2.8
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Table 2. Mutations detected in our study, divided by classes according to the phenotype observed
in patients in whom they were identified. Mutations in bold were described by us for the first
time worldwide.
Mutations Detected in Patients with a Classic Phenotype
Missense Nonsense Frameshift Splicing sites
p.M1T p.Q57X c.124_125delTA IVS2 2>G
p.L54F p.W162X c.428dupC IVS3+1G>A
p.E59K p.R220X c.583insGAATA IVS4+5G>T
p.R112C p.R227X c.614delC IVS5+1G>T
p.G116A p.E341X c.618del10 + c.629insA
p.Y152H p.C382X c.666delC
p.A156V c.718_719delAA
p.D165H c.846_847delTC
p.D170N c.946delG
p.C172Y c.1163delTCC
p.G183A
p.G183S
p.Y184N
p.Y222D
p.C223Y
p.R227L
p.W236S
p.L243F
p.N249K
p.G261C
p.P265L
p.I270T
p.L275H
p.Q279H
p.Q279K
p.A288D
p.M290T
p.R301G
p.R342Q
p.I354K
p.R356G
p.R356Q
p.R356W
p.E358G
p.G361R
p.R363H
p.G373S
p.T412P
Mutations detected in patients with late-onset
Missense Cryptic exon
p.L19P
p.V22G
p.D33Y
IVS4+919G>A
p.M51I
p.I91T
p.R112H
p.F113L
p.K130E
P.I253T
p.N215S
p.T246I
p.M290L
p.R301Q
p.G395A
p.V413A
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Table 2. Cont.
Genetic Variants of Unknown Significance
Missense
p.N5D
p.R118C
p.R118H
p.S126G
p.A143T
p.D313Y
p.T385A
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Figure 1. Phenotype observed in 207 Probands with a mutation in the galactosidase alpha gene (GLA).
Table 3. Characteristics of the 471 subjects with a genetic alteration in the GLA gene identified
(Probands + relatives). GVUS, genetic variants of unknown significance. Enzyme activity is measured
in nmol/mL/h; normal values > 3 nmol/mL/h. LysoGb3 is measured n nmol/L; normal values
0.08–1.13 nmol/L.
Overall Patients Male Patients Female Patients
Patients (%) 471 185 (39.3%) 286 (60.7%)
Average age [min-max] 40.2 [0–85] 40.1 [0–73] 40.2 [1–85]
Average ↵-Gal A activity 4.1 1.9 5.6
Average LysoGb3 9.7 19.8 2.6
Classic Phenotype Patients Male Patients Female Patients
Patients (%) 172 78 (45.3%) 94 (54.7%)
Average age [min-max] 38.2 [0–85] 39.3 [0–63] 37.3 [6–85]
Average ↵-Gal A activity 2. 0.1 3.9
Average LysoGb3 20.3 38.0 4.6
Late-Onset Patients Male Patients Female Patients
Patients (%) 111 47 (42.3%) 64 (57.7%)
Average age [min-max] 40.2 [0–78] 45.5 [0–73] 36.2 [6–78]
Average ↵-Gal A activity 2.4 0.5 3.7
Average LysoGb3 3.8 5.0 2.1
GVUS Patients Male Patients Female Patients
Patients (%) 188 60 (31.9%) 128 (68.1%)
Average age [min-max] 41.9 [1–85] 36.7 [1–77] 44.2 [1–85]
Average ↵-Gal A activity 7.2 5.5 8.1
Average LysoGb3 0.9 0.8 0.9
74.1% of the 81 mutations detected in our study are missense mutations, 12.4% are insertions or
deletions of nucleotides that cause a frameshift during translation and the formation of a premature
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stop codon, 7.4% are nonsense mutations, 4.9% are mutations in the splicing sites involved in the
regulation of mRNA maturation, and 1.2% are mutations in the cryptic exon of the gene (Figure 2).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 13 
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Figure 2. Classes of mutations that we found in the coding and regulatory regions of the GLA gene.
71.6% of the 81 mutations detected were found in patients who had a classic phenotype of FD
(58 mutations), 19.8% (16 mutations) were found in patients with late-onset phenotype and mild
symptoms, and 8.6% (7 mutations) were found to be a genetic variant of unknown significance (GVUS)
(Table 4). Regarding the 207 Probands, 34.8% of them (72 patients) had a classic phenotype, 17.9%
(37 patients) had late-onset, and 47.3% (98 patients) had a GVUS (Table 4). Concerning the total of
471 subjects with a mutation in the GLA gene, 36.5% of them (172 subjects) had a mutation associated
with classic phenotype, 23.6% (111 subjects) had a mutation associated with with late-onset, and 39.9%
(188 subjects) had a GVUS (Table 4).
Table 4. Phenotype associated with 81 mutations detected in individuals with a mutation in the GLA
gene, phenotype of 207 Probands, and 471 positives (Probands + relatives)in genetic test.
n. Mutations %Mutations n. Probands % Probands n. Positives % Positives
Classic 58 71.6% 72 34.8% 172 36.5%
Late-onset 16 19.8% 37 17.9% 111 23.6%
GVUS 7 8.6% 98 47.3% 188 39.9%
Overall 81 207 471
In 47.2% of the 72 Probands with a classic phenotype, the diagnostic hypothesis of FD was
advanced by a nephrologist, in 19.4% by a cardiologist, in 13.9% by a neurologist, in 11.1% by a
pediatrician, in 5.6% from a metabolic diseases unit, and in 2.8% from another origin (Table 1 and
Figure 3). In 37.9% of the 37 Probands with a late-onset phenotype, the diagnostic hypothesis of FD
was advanced by a cardiologist, in 27% by a pediatrician in the context of neonatal screenings, in
18.9% by a neurologist, in 13.5% by a nephrologist, and in 2.7% from another origin (Table 1 and
Figure 3). In 38.8% of the 98 Probands with a GVUS, the diagnostic hypothesis of FD was advanced by
a nephrologist, in 32.6% by a neurologist, in 10.2% by a cardiologist, in 9.2% by a pediatrician, in 4.1%
from a internal medicine unit, in 1% from a metabolic diseases unit, and in 4.1% from another origin
(Table 1 and Figure 3).
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In all 125 male patients harbouring a mutation in the GLA gene that is associated with the classic
or late-onset phenotype, the activity of the enzyme ↵-Gal A was always below normal values (Table 5).
In the 158 female patients with the same mutations, the enzyme activity showed variability, with a
range from pathologic to normal values (Table 5). In particular, only in 46% of female patients the
enzyme activity was below normal values, while in 54% it was normal. Regarding the measurement of
accumulation of LysoGb3 in blood, we found pathological values in all male patients with a mutation
in the GLA gene causative of FD: the accumulation is remarkable (both in the average values and in
the maximum value) in subjects with a mutation associated with classic phenotype, while it is modest
in individuals with mutation associated with a late-onset variant (Table 5 and Figure 4). A blood
accumulation of LysoGb3was also found in 56.8% of female patients with a mutation in GLA associated
with classic phenotype and in 40.1% of females with a mutation associated with late-onset variant; the
values in both cases were lower than values found in males with the same type of mutations (Table 5
and Figure 4).
Table 5. Enzyme activity and blood accumulation of LysoGb3 in 471 patients studied.
↵-Gal A Activity % Patients with LysoGb3 in Blood Average LysoGb3 [min-max]
Classic Phenotype Males Null or almost null 100% 38.0 nmol/L [4.8–137.2]Females Variable 56.8% 7.2 nmol/L [3.1–16.2]
Late-onset
Males Residual 100% 5.0 nmol/L [2.3–15]
Females Variable 40.1% 3.2 nmol/L [2.5–3.6]
GVUS
Males Normal 0  
Females Normal 0  
Healthy controls Males Normal 0  Females Normal 0  
In all the samples that came to our attention, we also studied the intronic portions flanking the
exons of the GLA gene. In 1.7% of the subjects positive in the genetic test, we found alterations in the
splicing sites that were involved in the regulation of gene expression. All male patients studied by
us with these mutations showed signs and symptoms attributable to the classic form of the disease,
high levels of LysoGb3 in blood, and absent or strongly reduced ↵-Gal A activity. In four patients,
we found the IVS4 + 919G > A mutation, already reported in the literature as associated with the
late-onset, cardiac variant of FD [15].
We also found mutations in the non-coding regions of the GLA gene, located outside of splicing
sites, most of which are grouped into haplotypes. The prevalence of these intronic mutations in
patients with a symptomatology attributable to FD (28%) was approximately 2-fold higher than the
prevalence observed in the control population (13%). All these patients have normal enzyme activity
and no LysoGb3 accumulation in blood; therefore, they cannot be considered as being affected by FD.
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3. Discussion
The increase in population screening in recent years has led to the identification of a large number
of genetic variants (mutations). A mutation can be clearly related to a disease and therefore explain the
phenotype of a patient, but not all genetic variants are responsible or co-responsible for a particular
disease or involved in patient’s symptomatology. The pathogenicity of a mutation and its relation to
the clinical phenotype, in a patient, may remain unclear; some genetic variants can be polymorphisms,
individual variability. These considerations are particularly important for many inherited disorders,
including lysosomal storage disorders. In Fabry disease, to date more than 900 mutations in the GLA
gene have been identified, but a percentage of these are classified by scientific community as genetic
variants of unknown significance (GVUS). These mutations often pose a real problem with respect to
counseling, family screening, and treatment options. Various studies have investigated FD in newborn
screening and in screening of high-risk populations, to define appropriate criteria and parameters for
a reliable FD diagnosis [16–19]. FD is suspected based on clinical and anamnestic-familial data and
confirmed by the identification of a specific genetic alteration and by measuring ↵-galactosidase A
activity, which could be null or deficient. Moreover, an important diagnostic support could be given
by the determination of the enzyme substrates Gb3 and its derivative LysoGb3.
Our experience, based on about 17,000 subjects studied, shows that, in this relatively large and
genetically well-characterized cohort of patients, LysoGb3 levels in blood were significantly higher in
FD patients compared to healthy controls and to subjects with FD-like symptomatology, who were
suffering from cardiac or renal damage with a different origin than FD. In particular, considering
patients with a mutation in the GLA gene, LysoGb3 levels in blood were higher in patients with
the classic phenotype than subjects with mild phenotype (male patients with late-onset variants and
females). Subjects with a GVUS in the GLA gene had LysoGb3 levels in blood comparable to healthy
controls. In patients’ relatives, LysoGb3 levels were generally similar in same-sex patients and always
higher in males than in females. Blood levels of LysoGb3 are not closely related to age of patients,
and higher values were found in patients with more severe clinical manifestations. Interestingly,
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in patients with classic phenotype, LysoGb3 levels in blood were generally higher among males
with severe mutations, causing an incomplete synthesis of ↵-Gal A, such as frameshift or non-sense
mutations, which are responsible for the formation of termination codons during translation. LysoGb3
levels in bloodwere also high inmale patients with mutations in splicing sites, where regulation of gene
expression at the post-transcriptional level occurs. In patients treated with the enzyme replacement
therapy, LysoGb3 levels in blood were reduced, both in males and females. Female patients with FD
usually have a milder and more variable symptomatology than male subjects; the activity of ↵-Gal
A can result in the normal range, and a moderate accumulation of LysoGb3 in blood was present in
40–60% of them. This occurs because female patients are usually heterozygous, and they have organs
that are chimeras of normal and affected cells, since, during embryonic development, one of the two
X-chromosomes in each somatic cell becomes transcriptionally inactive (lyonization). Until some years
ago, these patients were considered carriers, but this idea was revised, and today we are aware that
they can develop organ damage and severe clinical manifestations as male patients [20].
The presence of LysoGb3 in patients with FD was reported for the first time by Aerts’ group
in 2008 when, analyzing Gb3 and other metabolites in plasma of Fabry subjects, he discovered that
LysoGb3 levels were markedly higher than those of Gb3 [21]. LysoGb3 is the deacylated form of
Gb3, and its origin in Fabry patients is due to the activity of the lysosomal enzyme acid ceramidase,
which converts the excess of Gb3 in LysoGb3. LysoGb3, unlike Gb3, is a soluble molecule and can
be more easily excreted from cells [22]. The production of lyso-lipids as a system to decrease cellular
accumulation seems to be a common strategy for various lysosomal storage diseases, and elevated
lyso-lipid levels have also been found in Krabbe disease (galactosylsphingosine) and Gaucher
disease (glucosylsphingosine) [23,24]. Further studies showed that the concentrations of LysoGb3
are particularly high in the liver and intestine. These observations led researchers to hypothesize
the existence of a “secret road”: confronted with the inability to degrade Gb3, in FD patients the
excess of Gb3 is converted into LysoGb3, which, once transported to the liver, is secreted from the
body via bile [25]. The correlation between plasma levels of LysoGb3 and the manifestations of Fabry
disease was established in several studies [26]. Furthermore, it is clear that in Fabry hemizygotes,
both in humans and mice, plasma LysoGb3 is already high at birth. Conversely, in female hemizygotes,
LysoGb3 is low at birth and increases gradually with age, and there seems to be a correlation with the
symptomatology [21]. Other studies reported the direct involvement of LysoGb3 in the pathogenesis
of Fabry disease, for its ability to establish inflammatory phenomena, and because LysoGb3 has
been shown to promote smooth muscle cell proliferation, which may contribute to the increased
intima-media thickening frequently observed in patients [27]. Other evidence suggesting a direct role
of LysoGb3 in the pathogenesis of FD is the correlation between life-time exposure to plasma LysoGb3
and disease severity [26]. LysoGb3 is often used in patients’ follow-up for evaluating the efficacy of
therapeutic treatment.
Our case-finding study emphasizes the importance of adding to diagnostic criteria for a FD
diagnosis the determination of LysoGB3 in blood and/or accumulation of Gb3 detected in biopsies.
This consideration is also applicable to screening studies, in which a significant number of subjects
with a variant in the GLA gene harbor a GVUS, as observed by Van der Toll et al. [28].
4. Materials and Methods
4.1. Patients
Peripheral blood was collected, using EDTA as an anticoagulant, from subjects with clinical
manifestations related to FD symptomatology and from Fabry patients’ relatives. The study was
approved by the Hospital Ethics Committee of the University of Palermo, and signed informed consent
was obtained from all participants.
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4.2. Genetic Analysis
DNA samples were isolated from whole blood by column extraction (QIAamp DNAMicro Kit,
Qiagen, Germany), and their concentrations were determined using a spectrophotometer. Eight pairs
of primers were designed for the analysis of eight target regions containing the seven exons of the
GLA gene, including the regulatory sequences flanking them and the cryptic exon. PCR products were
purified and sequenced to detect mutations using an automated DNA sequencer at BMR Genomics.
4.3. a-Galactosidase A Activity Assay
↵-galactosidase A activity was performed in all male patients and in female patients with a
positive GLA gene test. ↵-Gal A analysis was determined by the Dried Blood Filter Paper test (DBFP)
described by Chamoles et al. [29], with the following modifications: spot of 5.5 µL of blood in 6 mm
diameter circle paper was placed into a 96-well plate suitable for fluorimetric assays and incubated for
16 h at 37  C in a thermomixer; the reaction was terminated by the addition of 250 µL of 0.1 mol/L
ethylenediamine (pH 11.4). The fluorescence of background, which is not due to the specific enzyme
activity, was determined for each sample, performing another reaction in the presence of 0.15 mmol/L
1-deoxygalactonojirimycin (DGJ, the inhibitor of ↵-galactosidase A) in 0.15 mol/L citrate phosphate
buffer (pH 4.4). This background was subtracted from the fluorescence of the sample. In each assay,
we added positive and negative controls and a calibration curve with 4-methylumbelliferone.
4.4. LysoGb3 Determination
The determination of LysoGb3 in blood was performed as previously described by Polo et al. [30].
5. Conclusions
The significant number of patients studied in our case-finding project allowed us to observe that in
FD patients there is a complete correspondence between symptomatology, the presence of mutations in
the GLA gene, the activity of the enzyme ↵-galactosidase A, and the accumulation of LysoGB3 in blood
and/or accumulation of Gb3 detected in biopsies. In these patients, clinical manifestations are severe
in the absence of enzyme activity and in the presence of significant accumulation of Gb3/LysoGb3
(classic form); mild and/or organ-specific, in the presence of residual enzyme activity and modest
accumulation (late-onset variants); and mild or absent, in the presence of normal enzyme activity and
absence of substrates accumulation (GVUS). In our experience, LysoGB3 accumulation in blood can be
considered a useful marker for FD, like the Gb3 detectable in biopsies but much less invasive. Today,
we have elements to generate a reliable diagnostic algorithm (Table 6).
Table 6. Characteristics of subjects presenting a mutation in the GLA gene.
Mutation Symptomatology ↵-Gal A Activity LysoGb3 in Blood
Responsible for Classic Phenotype Systemic, severe Null or almost null Yes (high)
Responsible for Late-Onset Phenotype Single organ and/orlate-onset Residual Yes (low)
GVUS Mild or absent Normal No
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